Faculty profile

Derek Jonker

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma
Nature Communications · 2026
Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Cancer Research · 2026
Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.
JCO clinical cancer informatics · 2025

All 37 publications

Latest funding

A Randomized Phase III Trial of Preoperative Chemoradiotherapy vs Preoperative Chemotherapy for Resectable Gastric Cancer
CIHR · 2011 · Co-investigator
$1,690,827
The Use of Extended Peri-operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Randomized Controlled Trial
CIHR · 2010 · Co-investigator
$816,176

All 2 grants and awards

37 publications.

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Renouf DJ, Topham JT, Loree JM, Schaeffer DF, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Nature Communications2026

DOI: 10.1038/s41467-026-70120-z

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Topham JT, Beckmann HM, Karasinska JM, Loree JM, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Clinical Cancer Research2026

DOI: 10.1158/1078-0432.ccr-26-0793

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.

Nicholls DL, Xu MC, Zhan L, Sharma D, Hueniken K, Chiasson K, Wahba M, Brown MC, Grant B, Shapiro J, Karapetis CS, Simes J, Jonker D, Tu D, O'Callaghan C, Chen E, Liu G

JCO clinical cancer informatics2025

DOI: 10.1200/cci.24.00114 PMID: 40215447

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T

EClinicalMedicine20255 citations

DOI: 10.1016/j.eclinm.2024.102991

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial.

Zhang J, Kong W, Hu P, Jonker D, Moore M, Ringash J, Shapiro J, Zalcberg J, Simes J, Tu D, O'Callaghan CJ, Liu G, Xu W

Cancer medicine2023

DOI: 10.1002/cam4.5341 PMID: 36281472

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW

Nature communications2022

DOI: 10.1038/s41467-022-31199-2 PMID: 35750695

Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.

Auer RC, Ott M, Karanicolas P, Brackstone MR, Ashamalla S, Weaver J, Tagalakis V, Boutros M, Stotland P, Marulanda AC, Moloo H, Jayaraman S, Patel S, Le Gal G, Spadafora S, MacLellan S, Trottier D, Jonker D, Asmis T, Mallick R, Pecarskie A, Ramsay T, Carrier M, PERIOP-01 investigators

BMJ (Clinical research ed.)2022

DOI: 10.1136/bmj-2022-071375 PMID: 36100263

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Renouf DJ, Loree JM, Knox JJ, Topham JT, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M

Nature Communications2022156 citations

DOI: 10.1038/s41467-022-32591-8

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M

Current oncology (Toronto, Ont.)2021

DOI: 10.3390/curroncol28030185 PMID: 34073199

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm.

De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Gagno S, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G

Cancers2021

DOI: 10.3390/cancers13071705 PMID: 33916844

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Derek Jonker

Research

Latest papers

Latest funding

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial.

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm.

A Randomized Phase III Trial of Preoperative Chemoradiotherapy vs Preoperative Chemotherapy for Resectable Gastric Cancer

The Use of Extended Peri-operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Randomized Controlled Trial

Frequent collaborators

Chantal Guillemette

Stephen Welch

Brandon Meyers

Terence Moyana

Geoffrey Liu

Rakesh Goel

John Hilton

Lesley Seymour

Pingzhao Hu

Paul Wheatley-Price

Libni Eapen

Michael Fung-Kee-Fung

Brian Hutton

Paul Karanicolas

Ming-Sound Tsao

Justin Presseau

Wei Xu

Erin Kennedy

Kednapa Thavorn

Mads Daugaard

Faiyaz Notta

Marc Carrier

Janet Dancey

Anna Tinker

Simron Singh

Eric Winquist

Kednapa Thavorn